{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:04:34Z","timestamp":1777482274031,"version":"3.51.4"},"reference-count":51,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Despite advances in therapy of Hodgkin's lymphoma (HL), a proportion of patients will not respond or relapse. The authors had previously identified CD25, IL-2R\u03b1, as a target for systemic radioimmunotherapy of HL since most normal cells do not express CD25, but it is expressed by a minority of Hodgkin\/Reed-Sternberg (HRS) cells and most Tregs rosetting around HRS cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design and Treatment:<\/jats:title>\n                    <jats:p>\n                      This was a single institution, nonrandomized, open-label phase I\/II trial of radiolabeled\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab, an anti-CD25 monoclonal antibody, BEAM (carmustine, etoposide, cytarabine, and melphalan) conditioning treatment followed by autologous hematopoietic stem cell transplant (ASCT). Four patients with refractory and relapsed HL were treated in this trial with 3 patients receiving a single dose of 564.6\u2013574.6 MBq\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab and the fourth patient receiving two doses of 580.9\u2013566.1 MBq\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab followed by high-dose chemotherapy and ASCT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      All 4 evaluable patients treated with\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab obtained complete responses (CRs) that are ongoing 4.5\u20137 years following their stem cell transplant.\n                    <\/jats:p>\n                    <jats:p>The spectrum and severity of adverse events were mild and more importantly none of the patients, including several with multiple therapies before this treatment, developed the myelodysplastic syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>\n                      Targeting by daclizumab was not directed primarily at tumor cells, but rather the nonmalignant CD25-expressing T cells adjacent to the HRS cells and\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab provided strong enough \u03b2 emissions to kill CD25-negative tumor cells at a distance by a crossfire effect. Furthermore, the strong \u03b2 irradiation killed normal cells in the tumor microenvironment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab (anti-CD25), high-dose BEAM chemotherapy and ASCT was well tolerated and yielded sustained complete remissions in all 4 patients with recurrent HL patients who completed their treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>\n                      Despite advances, a proportion of patients with HL will not have a CR to their initial treatment, and some with CRs will relapse. They demonstrated that the addition of\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab into the preconditioning regimen for refractory and relapsed HL patients with high-dose BEAM chemotherapy and ASCT provided sustained CRs in the 4 patients studied. Two of these patients were highly refractory to multiple prior treatments with bulky disease at entry into this study, including 1 patient who never entered a remission and had failed 6 different therapeutic regimens. Despite the small number of patients treated in this study, the sustained clinical benefit in these patients indicates a highly effective treatment. The daclizumab was directed primarily not at HRS cells themselves but toward nonmalignant T cells rosetting around malignant cells.\n                      <jats:sup>90<\/jats:sup>\n                      Y provided strong \u03b2 emissions that killed antigen nonexpressing tumor cells at a distance by a crossfire effect. Furthermore, the strong \u03b2 radiation killed normal cells in the tumor microenvironment that nurtured the malignant cells in the lymphomatous mass. The present study supports expanded analysis of\n                      <jats:sup>90<\/jats:sup>\n                      Y-daclizumab as part of the regimen of ASCT in patients with refractory and relapsed HL.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cbr.2019.3298","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T09:19:31Z","timestamp":1586510371000},"page":"249-261","source":"Crossref","is-referenced-by-count":11,"title":["<sup>90<\/sup>\n                    Y-Daclizumab (Anti-CD25), High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan Chemotherapy and Autologous Hematopoietic Stem Cell Transplant Yielded Sustained Complete Remissions in 4 Patients with Recurrent Hodgkin's Lymphoma"],"prefix":"10.1177","volume":"35","author":[{"given":"Kevin C.","family":"Conlon","sequence":"first","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Sportes","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Gress","sequence":"additional","affiliation":[{"name":"Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milos D.","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Radiation and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Millie A.","family":"Whatley","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Radiation and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonita R.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Corcoran","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen A.","family":"Kurdziel","sequence":"additional","affiliation":[{"name":"Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang H.","family":"Paik","sequence":"additional","affiliation":[{"name":"Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Fleisher","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, NIH Clinical Center, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge A.","family":"Carrasquillo","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Radiation and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"e_1_3_6_2_2","unstructured":"Noone AM Howlader N Krapcho M et al. (eds). SEER Cancer Statistics Review 1975\u20132015. Bethesda MD: National Cancer Institute. Online document at https:\/\/seer.cancer.gov\/csr\/19752015 based on November 2019 SEER data submission."},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199302253280808"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1516107112"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272102"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1409"},{"key":"e_1_3_6_7_2","first-page":"744","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med","volume":"353","author":"Diehl V","year":"2005","unstructured":"Diehl V, , Franklin J, , Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003; 348:2386; dosage error in text corrected in N Engl J Med, 2005; 353:744.","journal-title":"2003; 348:2386; dosage error in text corrected in N Engl J Med"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/13.S1.57"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1803"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.8526"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.2.403"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.8.1622"},{"key":"e_1_3_6_15_2","first-page":"917","article-title":"Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01","volume":"9","author":"Vriesendorp HM","year":"1991","unstructured":"Vriesendorp HM, , Herpst JM, , Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol, 1991; 9:917.","journal-title":"J Clin Oncol"},{"issue":"10","key":"e_1_3_6_16_2","first-page":"3324s","article-title":"Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease","volume":"5","author":"Vriesendorp HM","year":"1999","unstructured":"Vriesendorp HM, , Quadri SM, , Wyllie CT, et al. Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res, 1999; 5(10suppl):3324s.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3280678042"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.098"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10029"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111379"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.126.4.1393"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90003-0"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801153380304"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000155049.26787.45"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.12.6.769"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2711"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2003.12.005"},{"key":"e_1_3_6_30_2","first-page":"268","article-title":"Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution","volume":"40","author":"Carrasquillo JA","year":"1999","unstructured":"Carrasquillo JA, , White JD, , Paik CH, et al. Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med, 1999; 40:268.","journal-title":"J Nucl Med"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.019943"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.5.1381.bloodjournal8551381"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.3.616"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.5.1193.1193"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4689"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700838"},{"key":"e_1_3_6_37_2","first-page":"221","article-title":"New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group","volume":"20","author":"Josting A","year":"2002","unstructured":"Josting A, , Franklin J, , May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 2002; 20:221.","journal-title":"J Clin Oncol"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi119"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002965"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199310213291702"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199308123290703"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1413"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270538"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2245"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.9453"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.88"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1089\/108497802753773775"},{"key":"e_1_3_6_49_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1037"},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1199-y"},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2317"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-006-9060-0"}],"container-title":["Cancer Biotherapy and Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cbr.2019.3298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cbr.2019.3298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:15:27Z","timestamp":1777385727000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cbr.2019.3298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1089\/cbr.2019.3298"],"URL":"https:\/\/doi.org\/10.1089\/cbr.2019.3298","relation":{},"ISSN":["1084-9785","1557-8852"],"issn-type":[{"value":"1084-9785","type":"print"},{"value":"1557-8852","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}